CClinicalTrials.gg
Status unknownNCT05443139Updated Jan 18, 2023

Online Multi-component Psychological Intervention for Depression, Anxiety and Well-being in 7 Countries

An interventional study of Well-being online in Anxiety, Depression and Wellbeing, sponsored by Universidad Internacional de Valencia. Status unknown at 8 sites in 6 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-18.

Sponsored by Universidad Internacional de Valencia · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates the effectiveness of an online Multi-component psychological intervention, that is focused on providing self-support to the population of 5 Latin American countries and 2 European Countries. The objectives of the intervention are: 1) To reduce the symptoms of anxiety and depression in the adult population, 2) To increase the levels of subjective well-being.

Read the detailed description

Anxiety and depression at clinically significant levels are associated with suicidal thoughts and behaviors. Furthermore, it is associated with the health-disease process in two ways: 1) variables that influence behavior, hindering people's healthy habits and promoting the development of unhealthy behaviors; 2) anxiety and depression affect the psycho physiological activation of people, which affects their immune system.

Considering the damage that can occur by not addressing incipient problems of anxiety and depression, it is important to develop interventions with preventive purposes. Thus, the online modality of the intervention presented in this project can benefit a significant number of people in Mexico, Ecuador, Chile, Brazil, Peru, the Netherlands and Spain. The online modality of psychological interventions is a viable treatment alternative, especially for those people who do not have any psychological treatment within their reach.

The participants will be measured at pre, middle treatment, post assessment and two follow ups of 3 and 6 months. The self-report measures will include the following Psychometrics:

  1. General Anxiety Disorder with 7-items (GAD-7)
  2. Center for Epidemiologic Studies Depression Scale" in its revised version (CESD-R).
  3. Perceived Stress Scale (PSS-10)
  4. Pittsburgh Sleep Quality scale (PSQI)
  5. Action Acceptance Questionnaire II (AAQ-II)
  6. The Satisfaction with Life scale
  7. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS)
  8. Perceived Deficits Questionnaire (PDQ-5)
  9. The Positive and Negative Affect Schedule (PANAS)
  10. Opinion on the treatment.
  11. System usability scale.
  12. Client Satisfaction Questionnaire (CSQ-8S)
  13. The Telehealth Usability Questionnaire (TUQ)
02

Conditions studied

  • Anxiety
  • Depression
  • Wellbeing
  • Stress
03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's planned enrollment of 200 is above the median of 84 across 6,720 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Universidad Internacional de Valencia is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18 years or older
  • Completion of 100% of the basal evaluation through the form
  • Residence in one of the countries participating in the study
  • Fluency/ proficiency in Spanish (Mexico, Ecuador, Chile, Peru and Spain), Dutch or English (Netherlands) or Portuguese (Brazil), depending on the country.

Exclusion criteria

Exclusion Criteria:

  • Participants with severe symptoms of anxiety and/or depression, or they report a diagnosis of a depression and/or an anxiety disorder.
  • Participants who self-report having another diagnosed psychiatric comorbidity: personality disorder, psychotic disorder, bipolar disorder, Attention-Deficit/Hyperactivity Disorder, or others.
  • Participants taking medication for symptoms of depression and/or anxiety
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Interactive intervention

    The participants will receive a self-applied intervention composed by 10 sessions following a multi component structure. The participants assigned to this condition will count with interactive resources such as Videos, Online Forum and Exercises embedded on the platform.

    Behavioral: Well-being online

  • Experimental
    non-interactive intervention

    Self-administered treatment with 10 sessions will be provided through care manuals in PDF format within the same web platform. Participants in this group will receive a manual within the platform with the same content of the sessions as the experimental group but in PDF format.

    Behavioral: Well-being online

  • No intervention
    Waiting List group

    The control condition consists of a 30-day waiting list, in which participants will not be able to access the interventions. After the waiting process, they will be given access to either the interactive intervention or the non-interactive intervention.

Interventions

  • BehavioralWell-being online

    Multi component Intervention composed 10 sessions following a structure based on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Positive Psychology (PP), Mindfulness and Behavioral Activation Therapy (BAT).

06

What researchers measure

Primary outcomes

  1. Decrease in the scores of the Center for Epidemiologic Studies Depression (CESD-R) scale

    Center for Epidemiologic Studies Depression (CES-D) is a structured self-report scale for evaluation depression symptoms. This scale assesses the number of depression symptoms within 2 weeks. The scale consists 20 items and contains 4-point score responses (0 to 3) as the following; rarely or none of the time (less than 1 day); some of a little of the time (1-2 days); occasionally or moderate amount of time (3-4 days) and most or all of the time (5-7 days). The total possible range of scores is from 0 to 60 where \^16 is the cut-off point for this scale, and higher scores indicate more symptoms of depression. It is expected a statistically significant decrease (P \< 0.05) in depression symptoms.

    Time frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  2. Decrease in the score of the General Anxiety Disorder with 7-items (GAD-7) scale

    Is a short scale with items that measure the severity of generalized anxiety disorder symptoms. Responses are based on symptoms perceived during the past week. The questions of this scale are answered in Likert format with 0-3, where the maximum total score is 21. A score between 0 and 4 points indicates that anxiety is not perceived, and a score between 15 and 21 is an indicator of perceived severe anxiety.It is expected a statistically significant decrease (P \< 0.05) in anxiety symptoms.

    Time frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  3. Increase in Mental Psychological Well-being, the Warwick-Edinburgh Mental Well-being Scale (WEMWBS)

    It consists of 14 items, including hedonic (i.e. affects, life satisfaction) and eudaimonic (i.e. positive relationships, psychological functioning) items, which together measure mental well-being. Each item is responded in a Likert scale (i.e. 1 = none of the time to 5 = all of the time) and the total score ranges from 14 to 70. The higher the score, the higher the mental well-being

    Time frame: Time Frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

Secondary outcomes

  1. Decrease in The Perceived Stress Scale (PSS-10)

    The PSS-10 has ten items with 5 response options (0 = Never, 1 = Almost never, 2 = Sometimes, 3 = Often, 4 = Very often). The interpretation is that the higher the score, the higher the stress level

    Time frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  2. Decrease in the score of The Pittsburgh Sleep Quality Index

    This instrument assesses the quality patterns of sleep. It differentiates the "poor" and "good" sleep by measuring seven areas, where the range score of answers are from 0 to 3, the global sum of this scale can be a value between 0 to 60, and the cutoff point is "5" that indicates a "poor" sleep quality. It is expected a statistically significant increase (P \< 0.05) in the Sleep Quality measure.

    Time frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  3. Decrease in the Action Acceptance Questionnaire II (AAQ-II)

    The instrument measures experiential avoidance and psychological inflexibility. It consists of 7 items that are answered using a 7-point Likert scale. The items ask about the unwillingness to experience unwanted emotions and thoughts (e.g., "I am afraid of my feelings", "I worry about not being able to control my worries and feelings") and the inability to be in the present moment.

    Time frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  4. Increase in The Satisfaction with Life scale

    It consists of 5 items in which participants must indicate how much they agree with each question, with a response option in Likert format from 1 (strongly disagree) to 7 (strongly agree). The scores range from 5 to 35, where higher scores indicate greater satisfaction with life.

    Time frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  5. Decrease in the Perceived Deficits Questionnaire or PDQ-5

    The scale asks about problems of functioning in daily life associated with possible cognitive problems, with a 5-point Likert-type response format, ranging from 1- Rarely to 5-Always.

    Time frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  6. Decrease negative affect in the Positive and Negative Affect Schedule (PANAS)

    PANAS comprises two groups consisting of ten terms of either positive or negative affect. Partcipants assess their intensity on a 5-point scale ranging from "not at all" to "extremely", indicating the range of emotions at a given moment or over a period of time, and their chronic or transient nature.

    Time frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  7. Increase positive affect in the Positive and Negative Affect Schedule (PANAS)

    PANAS comprises two groups consisting of ten terms of either positive or negative affect. Partcipants assess their intensity on a 5-point scale ranging from "not at all" to "extremely", indicating the range of emotions at a given moment or over a period of time, and their chronic or transient nature.

    Time frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

07

Study locations

1 of 8 sites recruiting
08

References and documents

Publications

  • Piqueras Rodríguez, J. A., Martínez González, A. E., Ramos Linares, V., Rivero Burón, R., García López, L. J., & Oblitas Guadalupe, L. A. (2008). Ansiedad, depresión y salud (Anxiety, depression and health). Suma Psicológica, 15, 43-74.
  • Podlogar MC, Rogers ML, Stanley IH, Hom MA, Chiurliza B, Joiner TE. Anxiety, depression, and the suicidal spectrum: a latent class analysis of overlapping and distinctive features. Cogn Emot. 2018 Nov;32(7):1464-1477. doi: 10.1080/02699931.2017.1303452. Epub 2017 Mar 20. PubMed 28317414 ↗
  • Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. Cognit Ther Res. 2012 Oct 1;36(5):427-440. doi: 10.1007/s10608-012-9476-1. Epub 2012 Jul 31. PubMed 23459093 ↗
  • A-Tjak JG, Davis ML, Morina N, Powers MB, Smits JA, Emmelkamp PM. A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems. Psychother Psychosom. 2015;84(1):30-6. doi: 10.1159/000365764. Epub 2014 Dec 24. PubMed 25547522 ↗
  • Bolier L, Haverman M, Westerhof GJ, Riper H, Smit F, Bohlmeijer E. Positive psychology interventions: a meta-analysis of randomized controlled studies. BMC Public Health. 2013 Feb 8;13:119. doi: 10.1186/1471-2458-13-119. PubMed 23390882 ↗
  • Gal E, Stefan S, Cristea IA. The efficacy of mindfulness meditation apps in enhancing users' well-being and mental health related outcomes: a meta-analysis of randomized controlled trials. J Affect Disord. 2021 Jan 15;279:131-142. doi: 10.1016/j.jad.2020.09.134. Epub 2020 Oct 7. PubMed 33049431 ↗
  • Ekers D, Webster L, Van Straten A, Cuijpers P, Richards D, Gilbody S. Behavioural activation for depression; an update of meta-analysis of effectiveness and sub group analysis. PLoS One. 2014 Jun 17;9(6):e100100. doi: 10.1371/journal.pone.0100100. eCollection 2014. PubMed 24936656 ↗
  • Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. PubMed 16717171 ↗
  • Carleton RN, Thibodeau MA, Teale MJ, Welch PG, Abrams MP, Robinson T, Asmundson GJ. The center for epidemiologic studies depression scale: a review with a theoretical and empirical examination of item content and factor structure. PLoS One. 2013;8(3):e58067. doi: 10.1371/journal.pone.0058067. Epub 2013 Mar 1. PubMed 23469262 ↗
  • Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. No abstract available. PubMed 6668417 ↗
  • Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4. PubMed 2748771 ↗
  • Bond FW, Hayes SC, Baer RA, Carpenter KM, Guenole N, Orcutt HK, Waltz T, Zettle RD. Preliminary psychometric properties of the Acceptance and Action Questionnaire-II: a revised measure of psychological inflexibility and experiential avoidance. Behav Ther. 2011 Dec;42(4):676-88. doi: 10.1016/j.beth.2011.03.007. Epub 2011 May 25. PubMed 22035996 ↗
  • Diener E, Emmons RA, Larsen RJ, Griffin S. The Satisfaction With Life Scale. J Pers Assess. 1985 Feb;49(1):71-5. doi: 10.1207/s15327752jpa4901_13. PubMed 16367493 ↗
  • Strober LB, Binder A, Nikelshpur OM, Chiaravalloti N, DeLuca J. The Perceived Deficits Questionnaire: Perception, Deficit, or Distress? Int J MS Care. 2016 Jul-Aug;18(4):183-90. doi: 10.7224/1537-2073.2015-028. PubMed 27551243 ↗
  • Sevilla-Gonzalez MDR, Moreno Loaeza L, Lazaro-Carrera LS, Bourguet Ramirez B, Vazquez Rodriguez A, Peralta-Pedrero ML, Almeda-Valdes P. Spanish Version of the System Usability Scale for the Assessment of Electronic Tools: Development and Validation. JMIR Hum Factors. 2020 Dec 16;7(4):e21161. doi: 10.2196/21161. PubMed 33325828 ↗
  • Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063. PubMed 3397865 ↗
  • Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, Parkinson J, Secker J, Stewart-Brown S. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes. 2007 Nov 27;5:63. doi: 10.1186/1477-7525-5-63. PubMed 18042300 ↗

Individual participant data

Plan to share: Yes — The information will be available in a private server or in a server of the journal(s) that we will publish the articles that will be the result of this study. The protocol of the study is currently in progress to be published, in this article will be included such study protocol, the informed consent is already shared in the register of clinical trials.

Supporting information: Icf

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05443139
Lead sponsor
Universidad Internacional de Valencia
Collaborators
Universidad Autonoma de Ciudad Juarez, University of Guadalajara, Universidad Internacional del Ecuador, Universidad Santo Tomas, Tilburg University
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
Dec 23, 2022
Primary completion
Dec 23, 2023 (estimated)
Completion
Nov 1, 2024 (estimated)
Last update
Jan 18, 2023

Study contacts

Alejandro Domínguez Rodríguez, PhD
Contact
alejandro.dominguez.r@campusviu.es
+521 664 471 3277
Paulina Erika Herdoiza-Arroyo, PhD
Contact
pherdoiza@uide.edu.ec
+593 95 862 5451
Mercedes Almela Zamorano, PhD
study chair · Tilburg University
Reyna Jazmín Martínez Arriaga, PhD
study chair · University of Guadalajara
David Villarreal Zegarra, MD
study chair · Instituto Peruano de Orientación Psicológica
Leivy Patricia González Ramírez, PhD
study chair · Tecnologico de Monterrey
Adrián Antonio Cisneros Hernández, PhD
study chair · University of Guadalajara
Marinna Simões Mensorio, PhD
study chair · Independent Researcher
Rosa Olimpia Castellanos-Vargas, PhD
study chair · Universidad Autónoma de Ciudad Juárez
Rogéria Lourenço dos Santos, PhD
study chair · Independent Researcher
Joel Omar González Cantero, PhD
study chair · University of Guadalajara
Viviana Sylvia Vargas Salinas, PhD
study chair · Independent Researcher
Joaquín Mateu Mollá, PhD
study chair · Universidad Internacional de Valencia
Flor Rocío Ramírez Martínez, PhD
study chair · Universidad Autónoma de Ciudad Juárez
Antonio Carlos Santos da Silva, MD
study chair · Universidad Federal da Bahia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion